Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.065 SEK | +8.67% | +13.30% | -76.64% |
03-28 | Elicera Therapeutics AB Announces Director Changes | CI |
03-06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 37.37M 3.49M 4.75M |
---|---|---|---|---|---|
Net income 2024 * | -48M -4.48M -6.1M | Net income 2025 * | -34M -3.17M -4.32M | EV / Sales 2024 * | - |
Net cash position 2024 * | 35M 3.27M 4.45M | Net cash position 2025 * | 41M 3.83M 5.21M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.44
x | P/E ratio 2025 * |
-0.63
x | Employees | 2 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 38.42% |
1 day | +8.67% | ||
1 week | +13.30% | ||
Current month | +13.30% | ||
1 month | -6.99% | ||
3 months | -38.26% | ||
6 months | -78.27% | ||
Current year | -76.64% |
Managers | Title | Age | Since |
---|---|---|---|
Magnus Essand
FOU | Founder | 60 | 13-12-31 |
Di Yu
FOU | Founder | 39 | 13-12-31 |
Jamal El-Mosleh
CEO | Chief Executive Officer | 43 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-12-31 | |
Director/Board Member | 73 | 19-12-31 | |
Chairman | 68 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1.065 | +8.67% | 609,025 |
24-05-16 | 0.98 | +15.02% | 746,476 |
24-05-15 | 0.852 | -5.12% | 81,514 |
24-05-14 | 0.898 | -0.88% | 112,062 |
24-05-13 | 0.906 | -3.62% | 59,257 |
Delayed Quote Nasdaq Stockholm, May 17, 2024 at 11:29 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.64% | 3.21M | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- ELIC Stock